Clinical efficacy of sitagliptin as add-on to metformin, sulphonylurea or metformin-sulphonylurea combined therapy: a propensity score matched cohort study

被引：0
|
作者：
Idris, I. [1 ]
Mehta, R. [2 ]
Donnelly, R. [1 ]
Mamza, J. [1 ]
机构：
[1] Univ Nottingham, Sch Med, Royal Derby Hosp Ctr, Derby, England
[2] Univ Nottingham, East Midlands RDS EM, Res Design Serv, Nottingham NG7 2RD, England
来源：
DIABETIC MEDICINE | 2015年 / 32卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P428
引用
收藏
页码：159 / 160
页数：2
相关论文
共 50 条
  • [31] Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-year data
    Del Prato, S.
    Nauck, M.
    Duran-Garcia, S.
    Maffei, L.
    Rohwedder, K.
    Theuerkauf, A.
    Parikh, S.
    DIABETES OBESITY & METABOLISM, 2015, 17 (06): : 581 - 590
  • [32] Dapagliflozin plus saxagliptin plus metformin triple therapy vs sitagliptin add-on to metformin dual therapy in subgroups of patients with uncontrolled type 2 diabetes
    Del Prato, S.
    Handelsman, Y.
    Mathieu, C.
    Johnsson, E.
    Kurlyandskaya, R.
    Iqbal, N.
    Garcia-Sanchez, R.
    Rosenstock, J.
    DIABETOLOGIA, 2017, 60 : S20 - S21
  • [33] Oral Add-on Therapy to Metformin in Type-2-Diabetes mellitus: Canagliflozin and Sitagliptin in a direct Comparison
    Schnell, O.
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2014, 139 : S70 - S74
  • [34] Treat 4 Ramadan trial: a randomised control trial comparing liraglutide vs a sulphonylurea as add-on to metformin in patients with established type 2 diabetes
    Brady, E. M.
    Davies, M. J.
    Gray, L. J.
    Saeed, M. A.
    Hanif, W.
    Khunti, K.
    DIABETOLOGIA, 2013, 56 : S371 - S371
  • [35] Treat 4 Ramadan: A Randomised Control Trial Comparing Liraglutide vs. a Sulphonylurea as Add-On to Metformin in Patients With Established Type 2 Diabetes
    Davies, Melanie J.
    Brady, Emer M.
    Gray, Laura J.
    Saeed, Mujahid
    Wasim, Hanif
    Khunti, Kamlesh
    DIABETES, 2013, 62 : A661 - A661
  • [36] Efficacy and tolerability of taspoglutide versus pioglitazone in subjects with type 2 diabetes uncontrolled with sulphonylurea or sulphonylurea-metformin therapy: a randomized, double-blind study (T-emerge 6)
    Pratley, R. E.
    Urosevic, D.
    Boldrin, M.
    Balena, R.
    DIABETES OBESITY & METABOLISM, 2013, 15 (03): : 234 - 240
  • [37] EFFICACY AND SAFETY OF ANAGLIPTIN COMPARED WITH SITAGLIPTIN AS AN ADD-ON FOR PATIENTS WITH TYPE 2 DIABETES INADEQUATELY CONTROLLED WITH METFORMIN MONOTHERAPY
    Jin, S. -M.
    Park, S. W.
    Yoon, K. -H.
    Lee, M. -K.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2014, 106 : S135 - S136
  • [38] Continuous glucose profiles with vildagliptin versus sitagliptin in add-on to metformin: Results from the randomized Optima study
    Guerci, B.
    Monnier, L.
    Serusclat, P.
    Petit, C.
    Valensi, P.
    Huet, D.
    Raccah, D.
    Colette, C.
    Quere, S.
    Dejager, S.
    DIABETES & METABOLISM, 2012, 38 (04) : 359 - 366
  • [39] Imaging Metformin Efficacy as Add-On Therapy in Cells and Mouse Models of Human EGFR Glioblastoma
    Valtorta, Silvia
    Lo Dico, Alessia
    Raccagni, Isabella
    Martelli, Cristina
    Pieri, Valentina
    Rainone, Paolo
    Todde, Sergio
    Zinnhardt, Bastian
    De Bernardi, Elisabetta
    Coliva, Angela
    Politi, Letterio S.
    Viel, Thomas
    Jacobs, Andreas H.
    Galli, Rossella
    Ottobrini, Luisa
    Vaira, Valentina
    Moresco, Rosa Maria
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [40] Sulphonylurea-metformin combination therapy, cardiovascular disease and all-cause mortality: the Fremantle Diabetes Study
    Sillars, B.
    Davis, W. A.
    Hirsch, I. B.
    Davis, T. M. E.
    DIABETES OBESITY & METABOLISM, 2010, 12 (09): : 757 - 765
12345